New findings ‘alter forever how we think of MIGS’ – Dr Ike Ahmed
Ivantis has revealed new data from its five-year HORIZON pivotal trial showing its Hydrus Microstent device lowers the rate of ...
Tag: Ivantis
Alcon to acquire Hydrus Microstent MIGS device for AU$640 million
Multinational ophthalmic company Alcon has agreed to acquire privately-owned Californian firm Ivantis – and its Hydrus Microstent minimally invasive glaucoma ...
Ivantis to pay Glaukos US$60 million in MIGS patent settlement
MIGS device manufacturer Glaukos has reached an agreement with Ivantis over a patent infringement lawsuit regarding the latter’s Hydrus Microstent ...
Sector embraces government approval of standalone MIGS
From this month, surgeons can perform standalone minimally invasive glaucoma surgery (MIGS) under Medicare, seeing Australia become the first major ...